REVA Medical Inc
(ASX:RVA) has announced positive results from the first cohort of patients in relation to its FANTOM II clinical trial.
The company is currently testing the safety and performance of the Fantom bioresorbable coronary scaffold, which was implanted in 240 patients.
REVA says that this technology is an alternative to invasive metal stents, used to treat coronary artery disease.
The medical company also says that clinical follow-up of its patients showed a very low rate of Major Adverse Cardiac Events over the last six months.
REVA reported a net loss of $113.05 million at 31 December 2015.
